度洛西汀治疗躯体形式障碍33例

Study on Efficacy of Duloxetine in Treatment of Somatoform Disorders

目的观察度洛西汀治疗躯体形式障碍的临床疗效和安全性。方法将65例躯体形式障碍患者随机分为研究组(33例)和对照组(32例),治疗剂量分别为60 mg/d和100 mg/d,观察12周。采用汉密尔顿焦虑量表(HAMA)、临床大体印象量表(CGI)评定临床疗效,副反应量表(TESS)评定不良反应和安全性。结果研究组28例和对照组29例完成12周的观察。至12周末,研究组HAMA-躯体性焦虑因子分减分值平均为(2.8±2.0)分,对照组为(2.4±2.3)分,差异无统计学意义(P>0.05)。研究组临床总有效率为64.29%,对照组为58.62%,差异无统计学意义(P>0.05)。研究组不良反应发生率为34.6%,对照组为28.2%,差异无统计学意义(P>0.05)。结论度洛西汀治疗躯体形式障碍安全、有效。

Objective To investigate the clinical efficacy and safety of duloxetine in the treatment of somatoform disorder. Methods 65 patients with somatoform disorders were randomly divided into the study group（33 cases） and the control group （32 cases）. The study group and the control group were treated with duloxetine 60 mg/d and 100 mg/d for 12 weeks respectively. The Hamilton Anxiety Rat- ing Scale （HAMA） and the Clinical General Impression Scale（CGI） were used to evaluate the clinical efficacy. The Treatment Emergent Symptom Scale（TESS） was adopted to evaluate the adverse reactions and safety. Results 28 cases in the study group and 29 cases in the control group completed the 12-week observation. At the end of 12 weeks, the decrement value of somatic anxiety factor scores of HAMA was averagely 2.8-＋ 2.0 in the study group and 2.4±2.3 in the control group without statistical difference between the two groups（ P 〉0.05）. The clinical total effective rate was 64.29% in the study group and 58.62% in the control group without statistical difference between the two groups（P〉0. 05）. The incidence rate of adverse reactions was 34. 6%in the study group and 28.2%in the control group,which showed no statistical difference between the two groups （P 〉 0. 05）. Conclusion Duloxetine is effective and safe in the treatment of somatoform disorder.